A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910